Induced proximity can modulate otherwise undruggable disease proteins
PrimaryGeneral Proximity's causal theory is that many biological processes are controlled by physical proximity between target and effector proteins, and that small molecules can be discovered to induce useful target-effector proximity events. By bringing a disease-relevant target protein near an effector protein, the platform aims to cause functional modulation such as degradation, activation, refolding, re-localization, or re-programming. The testable prediction is that, for targets previously considered beyond the reach of conventional drug discovery, the OmniTAC/proximity discovery platform should identify target-effector pairings and small molecules that produce selective changes in target protein behavior and downstream disease biology. In the provided material, this is connected to age-related disease only indirectly through oncology programs, not to aging, lifespan, or healthspan biology specifically.
Popperian evaluation
The premise is biologically credible. Protein function often depends on physical proximity, and induced proximity already has a real mechanistic foothold through degradation, relocalization, and effector recruitment concepts. The theory also stays internally coherent: if a target protein lacks a conventional binding pocket, recruiting an effector protein can still alter its fate or activity. The weak point is breadth. Degradation, activation, refolding, re-localization, and re-programming are very different outcomes, so the general premise is stronger than any one claimed application.
Supporting evidence: The theory starts from the premise that many biological processes are controlled by physical proximity between target and effector proteins.; The causal chain is explicit: induced target-effector proximity should alter target behavior, then downstream disease biology.; The proposed modulation types include degradation, activation, refolding, re-localization, and re-programming.
Counter evidence: The provided material gives no publications or experimental examples for the specific OmniTAC platform.; The theory makes a broad claim across several distinct protein outcomes, and the evidence context does not show that each outcome has been achieved.
The theory explains why a platform might reach proteins that conventional small molecules struggle to affect: the molecule does not need to inhibit the target directly if it can bring the target near a useful effector. That is a real explanatory move. Still, the provided evidence has little observed biology to explain. We have a mechanistic thesis and company framing, plus indirect oncology relevance, but no shown target, pairing, molecule, assay result, disease response, or aging phenotype. At this stage, the theory explains a strategy better than it explains a body of evidence.
Supporting evidence: The prediction states that the platform should identify target-effector pairings for targets previously considered beyond conventional drug discovery.; The theory links proximity induction to selective changes in target protein behavior and downstream disease biology.; The provided material connects the approach indirectly to age-related disease through oncology programs.
Counter evidence: No publications are provided in the evidence context.; No direct aging, lifespan, or healthspan biology is supplied.; The material does not compare induced proximity against alternative explanations such as better screening, target selection, or ordinary ligand discovery.
The theory is testable in a clean way. Pick a target called undruggable, nominate an effector, discover or screen for proximity-inducing molecules, then measure target behavior, selectivity, and downstream disease biology. Failure can bite: no pairing, no molecule, no selective modulation, or no downstream effect would all damage the claim. The only softness is the word 'many'. A broad platform theory can survive a failed target by moving to another one unless the test set and success thresholds are defined before the experiment.
Supporting evidence: The prediction names concrete outputs: target-effector pairings and small molecules.; The predicted readouts include selective changes in target protein behavior and downstream disease biology.; The theory can be challenged target by target using biochemical, cellular, and disease-relevant assays.
Counter evidence: The evidence context does not define numerical success thresholds for selectivity, potency, durability, or disease-biology effect size.; The broad wording could allow failed targets to be dismissed as bad target choices rather than counted against the platform theory.
Reasoning tree
Public endorsements
Cognetta is not merely adjacent to the idea, he is the founder building the company around it. Public materials tie him to General Proximity directly, and the podcast summary says his chemical biology and small-molecule drug discovery work led him to create a proximity therapeutics platform and that he emphasizes the power of proximity in biological systems. That is a public endorsement of the core induced-proximity theory, even if the supplied excerpts do not spell out OmniTAC-style mechanisms in detail.
Evidence publication IDs: b9ed55d5-8320-44d7-bcfd-c3203ab2bb2e